US2016213706A1PendingUtilityA1

Treatment of myelosuppression

54
Assignee: CANTEX PHARMACEUTICALS INCPriority: May 9, 2012Filed: Jan 20, 2016Published: Jul 28, 2016
Est. expiryMay 9, 2032(~5.8 yrs left)· nominal 20-yr term from priority
Inventors:Stephen Marcus
A61P 7/00A61P 7/04A61P 35/02A61K 35/28A61N 5/00A61K 31/727A61K 45/06A61K 39/395
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods are presented for attenuating myelosuppressive side effects of treatment regimens, promoting thrombopoiesis and neutrophil production, and increasing efficacy of treatment regimens, by administering PF4-interacting heparinoids.

Claims

exact text as granted — not AI-modified
1 . A method of attenuating a myelosuppressive side effect of a patient treatment regimen comprising:
 adjunctively administering a therapeutically effective amount of a PF4-interacting heparinoid to the patient.   
     
     
         2 - 134 . (canceled)

Join the waitlist — get patent alerts

Track US2016213706A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.